The keys to the lock are immune checkpoints such as programmed cell-death ligand 1 (PD-L1), and its receptor PD-1; discovering this system earned Nobel Prizes for James Allison, at the University ...

Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

In interviews with Targeted Oncology, Ronan J. Kelly, MD, MBA, and David Zhen, MD, discuss the CheckMate 649 trial of ...

NICE says these patients taking Opdivo who had more PD-L1 (levels of 10% or more) on their cancer cells lived up to seven months longer than those with less. The committee have asked Bristol ...

Alphamab Oncology (stock code: 9966.HK) announced that the preclinical data on two novel bispecific antibody-drug conjugates (ADCs) JSKN021 and JSKN022 were presented as posters at the 2025 American ...

The first patient has been treated in a phase 1/2 clinical trial of an experimental Moderna vaccine designed to generate antibodies against PD-L1 and IDO1 – two targets thought to protect ...

While CTLA-4, PD-1, and PD-L1 are the primary focus of current ICIs, there are several other immune regulatory molecules that scientists are investigating as potential future targets for ICI therapies ...

Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...

The Swiss company was evaluating tiragolumab with its blockbuster PD-L1 inhibitor Tecentriq (atezolizumab ... with immunoglobulin and ITIM domain (TIGIT), which is upregulated by immune cells ...

In announcing (Chinese) ivonescimab’s Chinese approval in first-line PD-L1-positive non-small cell lung cancer on Friday, Akeso noted that the bispecific drug slashed the risk of death by 22.3% ...

The main function of RAD204 – a single domain monoclonal antibody – is its targeting of PD-L1, a protein which helps control the immune system and is overexpressed in many solid cancers.

The PFS benefit was demonstrated in patients with either PD-L1-positive or PD-L1-negative tumors. Akeso noted that no new safety signals were identified in this Phase III study. The full data set ...